PATENT CLAIM ANALYSIS

Application Number: 15953168
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["514", "179000"]

Abstract:
The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.

Claim (Index 38):
The pharmaceutical composition of  claim 37 , wherein the compound of Formula (I) is of the formula: or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 91.0
- Lexical Diversity: 1.97183
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14515441', '14907339', '14435790', '14301653', '15737683']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8113988456536004
- 35 USC 102 Novelty (BERT): 0.571904003786092
- Combined Prediction Score: 0.7874493614668496
- Mean Citation Score: 424.9461539999999
- Max Citation Score: 472.8585
- Similarity Product: 391.40533863329887

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test